| Primary hypogonadism
Natesto vs AndroGel
Side-by-side clinical, coverage, and cost comparison for primary hypogonadism.Deep comparison between: Natesto vs Androgel with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsAndrogel has a higher rate of injection site reactions vs Natesto based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Androgel but not Natesto, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Natesto
Androgel
At A Glance
Intranasal
Three times daily
Androgen
Topical
Daily
Androgen
Indications
- Primary hypogonadism
- Hypogonadotropic hypogonadism
- Primary hypogonadism
- Hypogonadotropic hypogonadism
Dosing
Primary hypogonadism, Hypogonadotropic hypogonadism 11 mg (2 pump actuations, 1 per nostril) administered intranasally three times daily (morning, afternoon, and evening, 6-8 hours apart) for a total daily dose of 33 mg; discontinue if total testosterone consistently exceeds 1050 ng/dL.
Primary hypogonadism, Hypogonadotropic hypogonadism Starting dose 40.5 mg testosterone (2 pump actuations or one 40.5 mg packet) applied once daily to upper arms and shoulders; titrate between 20.25 mg and 81 mg based on pre-dose morning serum testosterone at days 14 and 28 after starting or adjusting dose.
Contraindications
- Carcinoma of the breast or known or suspected carcinoma of the prostate
- Women who are or may become pregnant
- Women who are breast-feeding
- Carcinoma of the breast
- Known or suspected carcinoma of the prostate
- Pregnancy (can cause virilization of the female fetus)
Adverse Reactions
Most common (>=3%) PSA increased, headache, rhinorrhea, epistaxis, nasal discomfort, nasopharyngitis, bronchitis, upper respiratory tract infection, sinusitis, nasal scab
Postmarketing Myocardial infarction, stroke, venous thromboembolism
Most common (>=5%) PSA increased
Serious Nonfatal arrhythmias warranting intervention, atrial fibrillation, acute kidney injury, bone fracture
Postmarketing Myocardial infarction, stroke, polycythemia, prostate cancer, venous thromboembolism, sleep apnea, priapism, gynecomastia
Pharmacology
Testosterone is an endogenous androgen responsible for the normal growth and development of male sex organs and maintenance of secondary sex characteristics; Natesto delivers physiologic amounts of testosterone intranasally to restore deficient endogenous testosterone concentrations in hypogonadal men.
Endogenous androgen replacement; testosterone and dihydrotestosterone (DHT) are responsible for normal growth and development of male sex organs and maintenance of secondary sex characteristics, with male hypogonadism resulting from insufficient testosterone secretion due to gonadal defects (primary) or hypothalamic/pituitary failure (hypogonadotropic).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Natesto
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (9/12) · Qty limit (9/12)
Androgel
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (10/12) · Qty limit (0/12)
UnitedHealthcare
Natesto
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Androgel
- Covered on 4 commercial plans
- PA (5/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Natesto
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Androgel
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (0/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Natesto.
No savings programs available for Androgel.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
NatestoView full Natesto profile
AndrogelView full Androgel profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.